Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Generic Drugmaker to Sell Alternative to EpiPen Injectors

By Linda A. Johnson, AP Medical Writer | December 7, 2018

TRENTON, N.J. (AP) — Generic drugmaker Sandoz announced plans Thursday to start selling an alternative to the EpiPen in the U.S. early next year.

The EpiPen injector is used to halt life-threatening allergic reactions to insect bites, nuts and other foods. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.

Sandoz will sell prefilled syringes with the same medicine, the hormone epinephrine, under the name Symjepi. The price will be $250 for two, without insurance.

Two generic versions of EpiPen are sold in the U.S. for $300 a pair, including one from EpiPen seller Mylan. The company started selling its own generic after it was blasted for repeated hikes that pushed up its list price from $94 to $608 for a pair of brand-name EpiPens.

This image shows a new epinephrine prefilled syringe by Sandoz, Inc. Amid persistent shortages of EpiPens and other emergency autoinjectors that treat life-threatening allergic reactions, generic drugmaker Sandoz says that early next year it will launch a slightly cheaper rival in the U.S. Sandoz said Thursday, Dec. 6, 2018, that it plans to sell a pair of its generic autoinjectors for $250 without insurance. (Sandoz Inc. via AP)

What people pay varies, though, depending on insurance, discounts and the pharmacy.

Mylan’s injectors are made by a subsidiary of Pfizer, which is upgrading factories to fix quality problems. That resulted in production slowdowns. Pfizer said Thursday it’s shipping some injectors and expects to ship more in the coming months.

The shortages triggered temporary shortages of alternative products. As a result, U.S. regulators let some manufacturers extend expiration dates.

Sandoz, part of Novartis AG., will sell syringes with an adult dose made by Adamis Pharmaceuticals Corp. A children’s version will follow.

Israel’s Teva Pharmaceutical Industries began selling limited quantities of its new generic EpiPen in the U.S. last week.
___________________________________________________________

(Correction: The Associated Press originally reported erroneously that emergency allergy injector Auvi-Q was among products that had shortages because of an EpiPen shortage. Auvi-Q did not have shortages.)

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE